融创中国(01918.HK)获得2.8亿美元定期贷款融资
格隆汇8月20日丨融创中国(01918.HK)公布,于2019年8月20日,公司作为借款人,香港上海滙丰银行有限公司、中信银行(国际)有限公司、瑞士信贷银行股份有限公司新加坡分行、兴业银行股份有限公司香港分行、恒生银行有限公司、德意志银行新加坡分行、摩根士丹利及安泰商业银行股份有限公司作为贷款人,中国建设银行(亚洲)股份有限公司作为融资代理人,订立一份融资协议。据此,贷款人向公司提供合计金额为2.8亿美元的定期贷款融资,并且在任何银行或金融机构根据融资协议条款加入融资协议的前提下,总金额将增加至不超过4亿美元。融资期限为自融资协议日期起为期36个月,融资所得款项用于该集团现有债务再融资。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.